Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 23110523)

1.

Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW, Coonrod SA.

BMC Cancer. 2012 Oct 30;12:500. doi: 10.1186/1471-2407-12-500.

2.

Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.

Khurana A, McKean H, Kim H, Kim SH, mcguire J, Roberts LR, Goetz MP, Shridhar V.

Breast Cancer Res. 2012 Mar 12;14(2):R43.

3.

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.

Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.

Mol Cancer. 2013 Nov 11;12(1):134. doi: 10.1186/1476-4598-12-134.

4.

Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death.

Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR.

Cancer Biol Ther. 2008 Nov;7(11):1774-82. Epub 2008 Nov 12.

5.

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells.

Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA.

J Vis Exp. 2015 May 20;(99). doi: 10.3791/52727.

PMID:
26067809
6.

Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).

Scribner KC, Behbod F, Porter WW.

Oncogene. 2013 May 23;32(21):2631-9. doi: 10.1038/onc.2012.286. Epub 2012 Jul 9.

7.

Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.

Xiong G, Deng L, Zhu J, Rychahou PG, Xu R.

BMC Cancer. 2014 Jan 2;14:1. doi: 10.1186/1471-2407-14-1.

8.

Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer.

Wu X, Li Y, Wang J, Wen X, Marcus MT, Daniels G, Zhang DY, Ye F, Wang LH, Du X, Adams S, Singh B, Zavadil J, Lee P, Monaco ME.

PLoS One. 2013 Oct 14;8(10):e77060. doi: 10.1371/journal.pone.0077060. eCollection 2013.

9.
10.

A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.

So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, Maehr H, Uskokovic M, Zheng X, Conney AH, Cai L, Liu F, Suh N.

Mol Pharmacol. 2011 Mar;79(3):360-7. doi: 10.1124/mol.110.068403. Epub 2010 Nov 29.

11.

NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro.

Simmons MJ, Serra R, Hermance N, Kelliher MA.

Breast Cancer Res. 2012 Sep 19;14(5):R126. doi: 10.1186/bcr3321.

12.

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H.

Mol Cancer. 2009 Jun 8;8:34. doi: 10.1186/1476-4598-8-34.

13.

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.

Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R.

Breast Cancer Res. 2011;13(6):R131. doi: 10.1186/bcr3077. Epub 2011 Dec 16.

14.

Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.

Eilon GF, Gu J, Slater LM, Hara K, Jacobs JW.

Cancer Chemother Pharmacol. 2000;45(3):183-91.

PMID:
10663635
15.

Cullin-3 protein expression levels correlate with breast cancer progression.

Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W, Wu GS.

Cancer Biol Ther. 2012 Sep;13(11):1042-6. doi: 10.4161/cbt.21046. Epub 2012 Jul 24.

16.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

17.

An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D.

Breast Cancer Res. 2009;11(5):R66. doi: 10.1186/bcr2358. Epub .

18.

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD.

Breast Cancer Res. 2012 Jan 20;14(1):R16.

19.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ.

Clin Cancer Res. 2013 Jan 1;19(1):291-303. doi: 10.1158/1078-0432.CCR-12-1611. Epub 2012 Nov 7.

20.

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Wang W, Rayburn ER, Velu SE, Chen D, Nadkarni DH, Murugesan S, Chen D, Zhang R.

Breast Cancer Res Treat. 2010 Sep;123(2):321-31. doi: 10.1007/s10549-009-0638-0. Epub 2009 Nov 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk